Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFRONT: Avelumab, Radiotherapy, and Cyclophosphamide in R/M HNSCC
NCT03844763Phase 2Unknown
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jan 2019
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoints: Adverse Events at 4 months and Objective Response Rate. Status: unknown.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03844763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844763.